31 days
Time to First Decision

Precision Oncology, Volume 1, Issue 1

2026 March - 5 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (5)

Select all

Article

176 Views

19 Pages

Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases

Cynthia Lilieholm,
Adedamola O. Adeniyi,
Ohyun Kwon,
Jen Zaborek,
Caroline P. Kerr,
Hansel Comas Rojas,
Malick Bio Idrissou,
Carolina A. Ferreira,
Paul A. Clark and
Jamey P. Weichert
+ 6 authors

Precis. Oncol.2026, 1(1), 5;https://doi.org/10.3390/precisoncol1010005

2 March 2026

Rationale: Radium-223 dichloride (²²³RaCl₂) is an FDA-approved alpha-emitting radiopharmaceutical that targets bone metastases in metastatic castration-resistant prostate cancer (mCRPC). This study investigates the therapeutic and immunological effec...

Full Article

Case Report

152 Views

9 Pages

Metastatic Undifferentiated Melanoma with Ultra-High Tumor Mutational Burden and UV Mutational Signature: A Diagnostic Challenge

Nicole A. Lisek,
John L. Villano,
Derek B. Allison and
Lowell B. Anthony

Precis. Oncol.2026, 1(1), 4;https://doi.org/10.3390/precisoncol1010004

26 February 2026

Undifferentiated melanoma (UM) is a rare and diagnostically challenging subtype of malignant melanoma that often lacks traditional histological features and immunophenotypic expression. We report the case of a 58-year-old man with a history of a prev...

Full Article

Editorial

180 Views

2 Pages

Establishing a Prestigious Platform for Discovery, Innovation, and Excellence in Precision Oncology

Raul A. Urrutia

Precis. Oncol.2026, 1(1), 3;https://doi.org/10.3390/precisoncol1010003

20 January 2026

It is with great honor and satisfaction that I write this introductory Editorial for the launch of Precision Oncology, focused on a transformational discipline in the field of precision medicine for cancer [...]

Full Article

Article

639 Views

17 Pages

A Mechanistic Dynamic Surrogate Framework for Personalized Radioactive Iodine Therapy in Metastatic Thyroid Cancer

Marie Fusella Giuntini,
Cyril Voyant,
David Taieb and
Dominique Barbolosi

Precis. Oncol.2026, 1(1), 2;https://doi.org/10.3390/precisoncol1010002

10 December 2025

Background/Objectives: Radioactive iodine (RAI) therapy is widely used to treat metastatic differentiated thyroid cancer. To investigate physiological determinants of treatment response, a mechanistic model was developed, formulated as a system of co...

Full Article

Case Report

1,719 Views

7 Pages

Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy

Leonardo Simonelli,
Sebastian James Khairkhahan,
Francesco Alessandrino,
Elizabeth Anne Montgomery and
Gina D’Amato

Precis. Oncol.2026, 1(1), 1;https://doi.org/10.3390/precisoncol1010001

20 August 2025

Background and Clinical Significance: Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms with low metastatic potential but a high recurrence rate. Approximately 60–80% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangemen...

Full Article

Precis. Oncol. - ISSN 3042-7614

Imprint